Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.

Two researchers working in a lab © Photo courtesy of the Laboratory of Industrial & Pharmaceutical Technology of the University of Bordeaux (France)

The Developing Paediatric Primaquine project will develop and prequalify primaquine in tablet strengths appropriate for children and develop optimal primaquine regimens so that one tablet equals one dose.

Primaquine has two key roles in malaria elimination: the radical cure of Plasmodium vivax and P. ovale, and blocking P. falciparum transmission. DPP’s research includes granule work, taste masking, a bioequivalence study and two field trials: one of vivax radical cure (Ethiopia) and a study of single low dose primaquine to block falciparum malaria transmission (Burkina Faso).

Although children aged under 5 years are the most vulnerable group affected by malaria, accounting for 67% (274,000) of all malaria deaths worldwide in 2019, there are currently no paediatric primaquine tablets or kids-friendly formulations approved by a stringent regulatory authority or prequalified by WHO. This is a major obstacle for global malaria elimination – particularly in Africa, home to 94% of malaria cases and deaths, but also countries with high burdens of P. vivax.  

Supported by a grant from EDCTP2 (the European and Developing Countries Clinical Trials Partnership), an African-European institutional consortium, the Developing Paediatric Primaquine (DPP) project will develop and prequalify primaquine in a range of tablet strengths appropriate for children (2.5, 3.75, and scored 5, 7.5 and 15 mg) and develop optimal primaquine regimens so that one tablet equals one dose.
Once the bioequivalence of the 15 mg generic tablet is confirmed and the biowaiver for the lower strengths is granted, the full range of primaquine tablets can be prequalified – permitting their use by national malaria control programmes – with potentially a big impact on global malaria.

“Getting these child-appropriate primaquine doses prequalified by the WHO could have a massive impact on malaria elimination and malaria deaths in African children. WHO prequalification would allow the child-appropriate doses to be distributed widely by malaria control programmes,” explained project coordinator Dr Bob Taylor of the Mahidol Oxford Tropical Medicine Research Unit (MORU).

To optimise the drug formulations and make the pills palatable to children, the DPP project will perform sensory studies to identify the best kid-friendly aromas to mask the bitter taste of primaquine and, in parallel, validate the use of these new tablets by conducting clinical and pharmacokinetic studies for curing P. vivax in Ethiopia and blocking the transmission of P. falciparum malaria in Burkina Faso. Moreover, granule formulations and bespoke packaging are new concepts that will also be developed to make primaquine more user-friendly and so improve adherence.

“Granules are really the most convenient form for small children, and we hope to obtain additional funds in anticipation that the WHO will call officially for primaquine granules. In the meantime, packaging flavoured primaquine tablets for children is the way to go,” said DPP project manager Dr Julie Nguyen Ngoc Pouplin, who is based at Réseau Médicaments et Développement (ReMeD).

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine project will launch its website. Intended for a broad audience, including malariologists, policy makers, regulatory authorities and curious members of the public, the site will present the DPP project roadmap, its different work packages and consortium partners, and provide updates on project progress.

The Developing Paediatric Primaquine project is part of the EDCTP2 programme supported by the European Union

Similar stories

Pint of Science Thailand is back

MORU Bangkok Public Engagement

Live and on-line from Bangkok! Be ready for Thursday 13th May, when Pint of Science Thailand will stream live from Bangkok. Join us via Facebook, YouTube or right here from the Pint of Science Thailand website as we journey from bacterial infections to viruses, discover how clinical trials work, and how scientific development is seen in the eyes of the law!

Innovative strategies for engaging communities with malaria research

MORU Bangkok Public Engagement

For World Malaria Day 2021, F1000 Research Blog spoke to Professor Phaik Yeong Cheah about her research focussed on drama and arts-based community engagement for malaria research, published with Wellcome Open Research.

Researchers call for access to Ivermectin for young children

MORU Bangkok Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

New report highlights growing concern of vaccine falsification

MORU Bangkok

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

MORU Bangkok Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

MORU Bangkok

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.